Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVT-1601 in preterm infants at risk for respiratory morbidities
NCT04007120Phase 1Completed
- Sponsor
- Respivant Sciences
- Start
- Oct 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of RVT-1601 in bronchopulmonary dysplasia (BPD) (2 arms), sponsored by Respivant Sciences. Primary endpoints: Change in heart rate, Change in blood pressure and 1 more. Started Oct 2019; status: completed.
02
Drugs
RVT-1601
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT04007120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04007120.